Simon Rule
Professor of Hematology
University of Plymouth / Derriford Hospital · Plymouth, United Kingdom
UK MCL expert who played a key role in clinical trials establishing BTK inhibitors in MCL treatment. Advisor to multiple international MCL trials.
Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial.
Lancet (London, England) · Oct 25, 2025
Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · Jul 10, 2025
Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors.
Haematologica · Jan 1, 2024
Matching-adjusted indirect comparison of acalabrutinib versus ibrutinib in relapsed/refractory mantle cell lymphoma.
Journal of medical economics · Jan 1, 2024